# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001731122-23-000573
Filing Date
2023-04-04
Accepted
2023-04-04 16:33:00
Documents
3
Period of Report
2023-04-04

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | FORM DEF 14A | e4559_def14a.htm | DEF 14A | 378392
2 | GRAPHIC | img_001.jpg | GRAPHIC | 1017491
3 | GRAPHIC | img_002.jpg | GRAPHIC | 1037777
| Complete submission text file | 0001731122-23-000573.txt |  | 3206378

Mailing Address 51 W 52ND STREET, 7TH FLOOR NEW YORK NY 10019-6163
Business Address 51 W 52ND STREET, 7TH FLOOR NEW YORK NY 10019-6163 800-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 208365999 | State of Incorp.: NV | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37606 | Film No.: 23798322
SIC: 2836 Biological Products, (No Diagnostic Substances)